Objective: To investigate the effect of ticagrelor on interleukin -6 (IL-6), tumor necrosis factor -α after percutaneous coronary intervention (PCI) treatment. Methods: From April 2014 and March 2016, 180 patients with PCI in our hospital were randomly divided into observation group (n=98) and control group (n=82). The control group was treated with clopidogrel, the observation group ticagrelor. IL-6, TNF-α, high sensitive C reactive protein (hs-CRP) and soluble cell differentiation antigen 40 Ligand (sCD40L) and maximum platelet aggregation rate (MPAR) were detected inthe two groups before and after treatment. Results: 1 d, 7 d and 28 d in the observation group after treatment, IL-6, TNF-α, hs-CRP and sCD40L were significantly lower than those in the control group (P<0.05); MPAR were (54.10±12.51)%, (41.03±13.20)% and (30.81±9.78)% 1 d, 7 d and 28 d after treatment in the observation group, significantly lower than those in the control group (P<0.05); The incidence of major adverse cardiovascular events in the observation group and the control group were 6.12% and 9.76%, the difference was not statistically significant (P>0.05). Conclusion: Ticagrelor can significantly reduce serum levels of inflammatory factors after PCI with good anti platelet aggregation and vascular protective effects. |
[1] 李燕,王立忠,张春来,等.替格瑞洛对择期行经皮冠状动脉介入治疗不稳定型心绞痛患者的疗效及安全性研究[J].中国全科医学,2015,23(15):1824-1827.
[2] 马颖艳,王艳霞,徐白鸽,等.替格瑞洛用于PCI患者抗血小板治疗的有效性和安全性研究[J].中国循环杂志,2014,26(1):54-55.
[3] 刘大一,王智昊.替格瑞洛在老年ST段抬高型心肌梗死患者急诊冠状动脉介入治疗中的应用[J].中国老年学杂志,2014,28(10):2638-2641.
[4] EKMEKCI A,CICEK G,ULUGANYAN M,et al.Admission hyperglycemia predicts inhospital mortality and major adverse cardiac events after primary percutaneous coronary intervention in patients without diabetes mellitus[J].Angiology:J Vas Dis,2014,65(2):154-159.
[5] LIU Y,WANG Y,ZHAO X,et al.GW26-e5389 Stress echocardiography predicts major adverse cardiovascular event after percutaneous coronary intervention in patients with acute myocardial infarction[J].JACC,2015,66(16):252-253.
[6] KIRTANE A J,SANDHU P,MEHRAN R,et al.Association between intraprocedural thrombotic events and adverse outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (a harmonizing outcomes with revascularization and stents in acute myocardial infarct[J].Am J Cardiol,2014,113(1):36-43.
[7] 杨伊萍,傅慎文,胡宪清,等.替格瑞洛在合并糖尿病的急性心肌梗死患者经皮冠状动脉介入治疗中的疗效[J].中国新药与临床杂志,2016,22(3):221-224.
[8] 孟宪丽,孟华,刘洪智,等.替格瑞洛治疗行PCI的ST段抬高型心肌梗死合并糖尿病患者效果观察[J].中国医院药学杂志,2015,35(15):1406-1409.
[9] 王兆翔,高翔,张宇,等.应用血栓弹力图比较替格瑞洛和氯吡格雷对PCI术后患者的血小板抑制效果及疗效[J].实用医学杂志,2015,31(16):2709-2711.
[10] 滕树恩,黄铮,谢晋国,等.不稳定型心绞痛患者择期PCI术后替格瑞洛抗血小板治疗晚期临床疗效及安全性评价[J].中国动脉硬化杂志,2016,24(6):591-594
[11] 胡建波,张源萍,何永铭,等.STEMI患者急诊PCI比伐芦定联合替格瑞洛的近期出血风险评估[J].重庆医学,2016,45(21):2933-2935
[12] 苏方成,赵芳.替格瑞洛配合急诊PCI治疗急性心肌梗死的临床疗效和安全性探讨[J].临床心血管病杂志,2015,24(1):27-30.
[13] 蒲春华,周鹏,王沛坚.急性心肌梗死患者急诊PCI术前使用负荷剂量替格瑞洛的安全性及有效性[J].山东医药,2014,36(36):1-3.
[14] 许骥,华琦,胡少东,等.替格瑞洛在老年STEMI患者急诊PCI中的疗效与安全性分析[J].首都医科大学学报,2015,35(1):73-77.
[15] 夏经钢,曲杨,胡少东,等.替格瑞洛对急性ST段抬高型心肌梗死患者行急诊介入治疗的中期随访[J].北京大学学报:医学版,2015,30(3):494-498. |
